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Abstract
Background: Focal screening and treatment (FSAT) of malaria infections has recently been introduced in Peru to
overcome the inherent limitations of passive case detection (PCD) and further decrease the malaria burden. Here,
we used a relatively straightforward mathematical model to assess the potential of FSAT as elimination strategy for
Plasmodium falciparum malaria in the Peruvian Amazon Region.
Methods: A baseline model was developed to simulate a scenario with seasonal malaria transmission and the
effect of PCD and treatment of symptomatic infections on the P. falciparum malaria transmission in a low endemic
area of the Peruvian Amazon. The model was then adjusted to simulate intervention scenarios for predicting the
long term additional impact of FSAT on P. falciparum malaria prevalence and incidence. Model parameterization
was done using data from a cohort study in a rural Amazonian community as well as published transmission
parameters from previous studies in similar areas. The effect of FSAT timing and frequency, using either microscopy
or a supposed field PCR, was assessed on both predicted incidence and prevalence rates.
Results: The intervention model indicated that the addition of FSAT to PCD significantly reduced the predicted
P. falciparum incidence and prevalence. The strongest reduction was observed when three consecutive FSAT were
implemented at the beginning of the low transmission season, and if malaria diagnosis was done with PCR.
Repeated interventions for consecutive years (10 years with microscopy or 5 years with PCR), would allow reaching
near to zero incidence and prevalence rates.
Conclusions: The addition of FSAT interventions to PCD may enable to reach P. falciparum elimination levels in low
endemic areas of the Amazon Region, yet the progression rates to those levels may vary substantially according to
the operational criteria used for the intervention.
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Background
Despite several decades of intense control efforts, malaria
remains an important public health problem in Peru, es-
pecially in the Amazon region where most (85%) of the
malaria cases occur, mainly due to P. vivax [1]. Increased
financial support from international donors, e.g., the
Global Fund-PAMAFRO Project (2005–2010), allowed
for the scaling-up of comprehensive malaria control
strategies such as the use of artemisinin-based
combination therapy (ACT) and the distribution of
long-lasting insecticidal mosquito nets (LLINs) [2].
During this period, malaria declined drastically in Peru
from 87,805 reported clinical cases in 2005 to 29,355
and 23,075 cases in 2010 and 2011, respectively. Since
2011, following the reduction of financial support allo-
cated to malaria control activities, malaria incidence
started to increase again with a doubling of clinical
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cases in 2013, highlighting the potential risk of rapid
malaria resurgence in the Amazon Region [1].
In contrast to the classical statement that the develop-
ment of acquired malaria immunity requires long-term
exposure and intense transmission, recent studies in
endemic countries of South America have reported a
large proportion of asymptomatic malaria infections
[3-12] suggesting that clinical immunity may develop as
well in low-transmission settings of the subcontinent.
The wider use of molecular diagnostics in epidemio-
logical studies allows for a better knowledge on the
extent of these asymptomatic infections, thus uncovering
a “hidden” human infectious reservoir likely to contrib-
ute in maintaining transmission in endemic areas [9,13].
Indeed, cross-sectional surveys conducted in rural com-
munities surrounding Iquitos city in Peru reported preva-
lence of asymptomatic parasite carriers ranging from 5 to
14%, mostly detectable only by PCR (sub-microscopic
infections) [3-5].
National malaria surveillance in the Amazon Region
relies on passive case detection (PCD) with microscopy
[14]. Patients presenting with fever or any other symp-
toms compatible with malaria are systematically tested
by microscopy at peripheral health facilities and treated
following national guidelines. However, the major limita-
tion of PCD is that asymptomatic individuals do not
seek medical care and therefore remain undetected and
untreated [4,15], extending the period of parasite
carriage [16]. Other described limitations of PCD in-
clude the quality of microscopy-based diagnosis [17], the
access to health services with available microscopy [18],
and social and cultural factors that influence treatment
seeking behaviour at community level [19].
Active case detection (ACD) has recently been
recommended in low transmission and malaria-elim-
ination settings to overcome the inherent limitations
of PCD and target the asymptomatic parasite reservoir
[20]. According to the World Health Organization
(WHO), ACD is defined as the detection of malaria in-
fections through household visits in population groups
that are considered to be at risk. In the Peruvian
Amazon, focal screening and treatment (FSAT), has
recently been introduced by the National Malaria Control
Program (NMCP) to target malaria hotspots and further
decrease the malaria burden. Malaria hotspots are well-
delimited villages in rural areas or neighborhoods in
periurban areas in which the cumulative malaria inci-
dence over the past 3–5 years is the highest. These hot-
spots represent ~10-20% of the total malaria reporting-
localities and account for more than 80% of the total cases
in the Region. The intervention consists of systematic
finger prick blood sampling of the whole population
(100–1000 inhabitants) during the period of highest inci-
dence (usually between February and May) and the
treatment of all microscopically positive infections, irre-
spective of the presence of symptoms [14]. Following the
national treatment guidelines, P. falciparum infections are
treated with an ACT -mefloquine and artesunate
(MQ-AS)-, and P. vivax infections with chloroquine (CQ)
and primaquine (PQ) [14]. However, due to the lack of
evidence-based guidelines [21,22], the criteria and proce-
dures to implement FSAT interventions in the Amazon
Region have often been arbitrarily decided and are subject
to annual variations in logistical and financial resources.
Mathematical models of various levels of complexity
have been used for understanding malaria transmission
dynamics and informing decision-making in malaria
control and elimination efforts [23-26]. Here, we used a
model to assess the long term impact of FSAT on the
P. falciparum malaria transmission intensity (MIT) in a
low endemic area of the Peruvian Amazon Region.
Retrospective data from a cohort study in a rural
community of the Peruvian Amazon were used to esti-
mate infection rates and a time-variant seasonal vector
parameter, and then to evaluate the model. Other
malaria-transmission parameters were obtained from pre-
viously published studies in the Amazon region. Eventu-
ally, the model was used to predict the potential reduction
in malaria transmission following the addition of FSAT to
the ongoing PCD, allowing for a simulation of the effect
size according to the diagnostic tools used, as well as the
timing and frequency of FSAT interventions.
Methods
Baseline model
An extension of the Anderson-and-May’s malaria trans-
mission model [27] and the corresponding differential
equations was used to simulate a scenario where sea-
sonal malaria transmission remains at similar levels each
year within a restricted human population with ongoing
PCD and treatment of symptomatic P. falciparum infec-
tions (Figure 1 and Additional file 1: Figure S1). The
deterministic model allows the human population (N) to
move between four different states (compartments), and
the mosquito population (M) between three states. Indi-
viduals initially start in a susceptible state (S) and become
infected at a rate that is determined by the mosquito
density (m), the human feeding rate per mosquito (a), the
infectiousness of the mosquito population (V/M), and the
susceptibility of an individual after being bitten by an in-
fectious mosquito (b). Individuals progress to the latent
state (E), from which they develop gametocytes in the
blood and become infectious after a latent period (l). Two
consecutive sub-states are distinguished in infected latent
individuals (E1 and E2) thus dividing the latent period into
two time intervals: between sporozoite inoculation and
development of detectable asexual stage parasites in
blood (l1), and between asexual parasite infection and
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development of gametocytes (l2). Then, the number of
individuals who move from E1 to E2 at time t is equal to
the number of individuals who entered E1 at time t-l1
adjusted by the factor e-l1*h, which incorporates the
human mortality rate (h) and the average time interval
for developing asexual blood parasites (l1). On the other
hand, infected individuals leave sub-state E2 at a rate (1/l2)
which is the reciprocal of average duration of the gameto-
cytogenesis process.
While a constant fraction (y) of symptomatic infections
of all newly infected individuals is routinely detected by
PCD and treated with an ACT of known effectiveness (ε)
within the treated state (T), the remaining fraction (1-y*ε),
including asymptomatic individuals and previously treated
individuals with parasitological treatment failure, remains
infectious in an untreated state (I) until the “spontaneous
cure” of the disease (i.e. clearance of all parasite forms)
unless they are actively detected and treated. Once
recovering from compartments T and I, individuals return
to the susceptible state (S). While recovery rate for treated
individuals (1/r1) is the reciprocal of average human infec-
tious period (i.e. length of time gametocytes remain in the
bloodstream) with effective treatment, recovery for un-
treated individuals requires they pass through two sub-
states before becoming recovered: those who have not yet
(I1) and those who have spontaneously cleared the asexual
blood stage parasites (I2). Then, the rate of movement of
individuals from I1 to I2 (1/r2a), and from I2 to S (1/r2b)
are the reciprocal of the average time for the spontaneous
clearance of asexual parasites from blood (r2a), and the
remaining average infectious period after the clearance of
blood asexual parasites (r2b), respectively in untreated
individuals.
Regarding the mosquito population (M), the model in-
cludes an initial susceptible state (U) for all mosquitoes,
becoming infected at a rate determined by the following
three parameters: human feeding rate per mosquito (a),
fraction of infectious individuals in the human popula-
tion ((T + I)/N), and the mosquito susceptibility to in-
fection after biting an infectious individual (c). Infected
mosquitoes remain in a latent state (L) for a specific
time period before developing sporozoites and becoming
infectious (V). The estimation of surviving mosquitoes
by the end of the latent period requires an adjustment
by the factor e-g*n which incorporates a constant mos-
quito mortality rate (g) and the average mosquito latent
period (n). The model assumes that mosquitoes remain
infectious until they die.
The main assumptions of this model are the following:
i) human and mosquito populations remain constant
(number of births and deaths are equal at any time); ii)
malaria-attributable deaths are not explicitly incorpo-
rated (malaria mortality rate is similar to general
mortality rate); iii) no individual differences in transmis-
sion parameters between subjects; iv) super-infections
do not occur [28]; v) all infected individuals develop
Figure 1 Schematic diagram of the human and vector model states. The human population (N) is divided into 4 compartments: susceptible (S),
infected latent (E), infectious treated (T) and infectious untreated (Ι) individuals. The latent period has 2 sub-states: latent which have not yet
developed asexual blood-stage parasites (E1) and latent with asexual blood-stage parasites (E2). Before becoming recovered, individuals in I
compartment need to pass through 2 sub-states: those who have not yet (Ι1) and those who have spontaneously cleared the asexual blood stage
parasites (Ι2). The mosquito population (M) is divided into 3 compartments: uninfected (U), infected latent (L) and infectious (V) mosquitoes. The
addition of FSAT to PCD allows for the detection and treatment of individuals in E2, I1 and I2 compartments.
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mature gametocytes immediately after they leave the la-
tent sub-state E2; vi) any gametocytemia represents po-
tential for transmission; and vii) there is no prophylactic
effect of the drugs post recovery.
Retrospective data on malaria cohort study
The model was fine-tuned by using retrospective data
from a cohort study carried out between 2003 and 2008
in four rural communities of San Juan district, south of
Iquitos city in the Peruvian Amazon [4,28,29]. Malaria
transmission in this area typically starts in January and
finishes in July with a peak of clinical malaria cases
between February and March; P. vivax and P. falciparum
infections occurring at a ratio 4:1. Previous reports from
this area indicated that more than two thirds of
P. falciparum infections were asymptomatic with low
parasite density [3,4]. Anopheles darlingi is the major
malaria vector with a strong anthropophilic behavior
[30,31]. The initial cross-sectional survey conducted in
April 2003 among cohort participants showed that most
of them reported sleeping under bed nets, although
none of them mentioned the use of insecticide treated
nets or repellents in their homes [4]. From 2004 to 2008,
biannual community screening campaigns were carried
out (beginning-end of each malaria season), and in be-
tween, weekly ACD for P. falciparum infections was
conducted, sampling each month a new group of indi-
viduals living within a 100-m radius of houses where at
least one P. falciparum infection was detected during
the previous month (index houses), either through the
surveys, ACD or the routine PCD at health facilities [4].
Since high coverage during screening campaigns was
achieved only in Ninarumi community, local model pa-
rameters were estimated from this community only, and
taking into account malariometric indices from the year
2004 only, which was the first full year of ACD in the
cohort study. The prevalence of P. falciparum infections
by microscopy in Ninarumi was measured at 6.5%
and 1.1%, respectively in January and August 2004
(Additional file 2: Table S1); and during that year a
total of 139 new P. falciparum infections were detected
(0.28 infections/person/year), 91 (65.4%) of them being
symptomatic either at the time of sampling or during
the following week. Of the additional 48 infections
which remained asymptomatic during the follow-up,
19 were confirmed only by retrospective PCR analysis
on blood samples collected on filter paper from indi-
viduals during weekly ACDs. The detailed procedures
for the PCR analysis are described elsewhere [29]. All
individuals enrolled in the cohort study gave signed in-
formed consent or assent. Ethical clearance was re-
ceived from New York University (NYU Institutional
Review Board [IRB] approval no. 08–982), the University
of Alabama at Birmingham, and the Peruvian Ministry of
Health and National Institutes of Health Internal Ethical
Review Boards [29].
Transmission parameter values
Considering days as the time unit, the model
parameterization was done in several steps, i.e. using
first the available cohort data for the estimation of im-
portant local parameters, and in a second step, using
published data to improve the first step estimates or to
set values for the remaining transmission parameters.
A systematic literature search was undertaken in different
databases (i.e. PubMed, EMBASE and SciELO) prioritizing
published studies on malaria in the Amazon Region in
English and Spanish language, especially those from the
Iquitos area when available. Additional searches were con-
ducted in Google and through reference tracking. Third,
when parameters could not be identified in previous steps,
they were estimated by fitting the model to the observed
clinical malaria incidence in Ninarumi. Table 1 summa-
rizes key parameter values used in the baseline model (see
Additional file 3: Text S1 for a detailed description).
FSAT model and assessment of interventions
In the scenario with FSAT interventions, the baseline
model was improved by allowing movements from sub-
states E2, I1 and I2 to the treated state (T) (red dotted
lines in Figure 1), at specific rates that are determined
by the coverage (Δ), the reciprocal of duration of the
intervention (1/v), the sensitivity of the diagnostic test
used for malaria screening (s), and the effectiveness of
treatment in confirmed infections (ε).
After setting initial conditions for human and mosquito
compartments based on the average observed prevalence
in the 2004 Ninarumi surveys and the reported A. darlingi
sporozoite rates in the area [30], the baseline model was
run until reaching steady levels (baseline scenario), indi-
cated by the stable cumulative number of P. falciparum
infections recorded for 20 more simulated years. Then,
the model was run for an additional year (year 0) after
which interventions based on FSAT (intervention sce-
nario) were added to the routine PCD (baseline scenario).
A first intervention scenario was modeled with the
following assumptions: one FSAT during the peak of the
high transmission season (only in February of year 1);
FSAT covers 100% of population (Δ = 1) in one day
(v = 1); microscopy used in FSAT allows for the detection
of 50% of asexual blood-stage infections by P. falciparum
(sub-states E2 and I1), and 10% of infections with only sex-
ual stages (gametocytes) in blood (sub-state I2) [32]; and
all detected P. falciparum infections are treated with a
98% effectiveness (ε = 0.98).
Additional intervention scenarios were modeled to
assess the impact of different operational criteria for
FSAT implemented during only one year (i.e. timing,
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number and time intervals between consecutive inter-
ventions) on the predicted cumulative incidence and
prevalence of P. falciparum infections. Besides micros-
copy, a field PCR was also considered as diagnostic test
during malaria screening, assuming sensitivities of 95%,
95% and 80% for detecting infections in sub-states E2, I1,
and I2, respectively. The predicted cumulative incidence
(i.e. cumulative number of new symptomatic and asymp-
tomatic infections) was recorded over one-year and five-
year periods from the start of the first FSAT in each
intervention scenario, and was compared with the cu-
mulative incidence found with the baseline PCD sce-
nario. The predicted impact of each intervention was
determined as the percentage difference between the cu-
mulative number of new P. falciparum infections with
baseline and with the respective intervention scenarios
(cumulative number of infections averted). In addition,
minimum and maximum predicted prevalence were de-
termined during both the first and the fifth year after
the onset of FSAT interventions. Finally, operational cri-
teria for implementing FSAT interventions during only
one year which had the strongest impact were used
again to assess the effect of the same interventions if im-
plemented during several consecutive years.
Malaria transmission scenarios were simulated in R
software version 2.15.3 (function “dede” in deSolve pack-
age) allowing to solve delay differential equations to take
into account latent periods for infected individuals and
mosquitoes before being infectious (see R code for base-
line model in Additional file 4: Text S2) [33]. Baseline
Table 1 Model parameters
Parameters Symbol Value Source
Baseline model parameters
Mosquito density (ratio female mosquitoes/humans) m 75 Assumed value within published range
Human feeding rate, bites per mosquito per day a 0.035 - 0.32 Monthly estimations from fitting cohort
data; values within published range
Mean: 0.088
Susceptibility of an individual to infection after being bitten
by an infectious mosquito
b 0.05 Estimation using cohort and published data
Mosquito susceptibility to infection after biting an infectious
individual
c 0.41 Published data
Duration of human latent period for Pf* in d]’ cays (l = l1+ l2) l 21 Published data
Duration from sporozoite inoculation to development of blood
asexual parasites in days
l1 11 Published data
Duration from asexual blood stage infection to development
of gametocytes in days
l2 10 Published data
Duration of mosquito latent period in days n 11 Published data
Daily human mortality rate h 0.00005 Published data
Daily mosquito mortality rate g 0.16 Published data
Fraction of symptomatic infections y 0.65 Cohort data
Treatment effectiveness ε 0.98 Published data
Duration of infectious period in treated humans with ACT (in days) r1 14 Published data
Duration of infectious period in untreated humans in
days (r2 = r2a + r2b)
r2 200 Published data
Duration of presence of blood asexual parasites in untreated humans
in days
r2a 80 Published data
Duration of infectious period in untreated humans after clearance
of blood asexual parasites in days
r2b 120 Published data
FSAT parameters
Coverage of FSAT Δ 1 Assumption
Duration of FSAT in days v 1 Assumption
Sensitivity of microscopy for detecting Pf* asexual stages s1a 0.5 Published data
Sensitivity of microscopy for detecting Pf*gametocytes s1g 0.1 Published data
Sensitivity of highly sensitive diagnostic tests for detecting asexual stages s2a 0.95 Assumption
Sensitivity of highly sensitive diagnostic tests for detecting gametocytes s2g 0.8 Assumption
*Pf = P. falciparum.
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model performance was examined by comparing pre-
dicted and observed P. falciparum incidence and preva-
lence from the cohort study. A Wilcoxon matched-pairs
signed-ranks test was used to test differences between
observed and predicted monthly incidence, with p < 0.05
indicating statistical significance. Different initial values
for the A. darlingi sporozoite rate (V/M) were tested
and did not affect the results. Moreover, a one-at-a-time
sensitivity analysis was conducted to determine the
effect of the following parameters on the baseline model
predictions [34]: the mosquito density (m), the human
feeding rate (a), the fraction of symptomatic infections
(y), and the treatment effectiveness (ε). Changes (in-
crease and decrease) of 20% in parameter values were
considered in the analysis. Finally, only human parame-
ters (y, ε) were used later to assess their impact on the
predictions of the intervention scenarios with FSAT.
Results
Baseline model predictions largely reflected P. falciparum
incidence rate in Ninarumi in 2004 (Figure 2A), with no
statistically significant difference between observed and pre-
dicted monthly incidence of symptomatic P. falciparum
infections. While Ninarumi reported 91 symptomatic and
38 asymptomatic P. falciparum infections (total = 139
infections) in 2004, the baseline model predicted 99 symp-
tomatic and 43 asymptomatic infections (total = 152 infec-
tions). Furthermore, predicted prevalence curves accurately
reflected the seasonal dynamics of malaria infections
(Figure 2B), with high transmission season (HTS) between
January and July, and low transmission season (LTS) be-
tween August and December. According to the baseline
model predictions, the maximum overall and microscopic-
ally determined prevalence during HTS were 12.3% and
6.2%, respectively; while the corresponding minimum
values during LTS were 3.4% and 0.7%, respectively. There-
fore, predicted and observed prevalence by microscopy also
correlated well in Ninarumi in 2004. Furthermore, the
proportion of detected infections by microscopy among
the total predicted infections was significantly higher in the
peak of HTS (~50%) than in LTS (~10-20%). Similarly, the
proportion of asymptomatic infections among the total pre-
dicted infections varied according to the season, from a
minimum of 58% during the peak of HTS to a maximum
of 96% in the middle of LTS.
The sensitivity analysis for the baseline model (Figure 3)
showed that with values above 0.7 for the fraction of
symptomatic infections (y), malaria transmission de-
creased progressively until almost undetectable levels.
In addition, seasonal malaria transmission persisted
only when mosquito density (m) and mean expected
number of bites on humans per mosquito (a) are
higher than 67 and 0.080, respectively. Increasing
monthly values of human feeding rate (a) by 20% had
by far the strongest effect on the annual incidence rate,
with more than three times the baseline number of
P. falciparum infections (~225% more infections)
(Figure 3A). On the other hand, a decrease from 0.65
to 0.5 in the fraction of symptomatic infections (y) had
the highest impact on the predicted incidence of
asymptomatic infections (increase of baseline inci-
dence by ~250%) (Figure 3B). Moreover, the same
changes in both parameters (i.e. human feeding rate and
fraction of symptomatic infections) had similar effects on
Figure 2 Comparison between observed and baseline model-predicted P. falciparum malariometric measures in Ninarumi village. Curves with
data from Ninarumi in 2004 were repeated for three consecutive years: A) observed and predicted P. falciparum monthly new P. falciparum
infections (monthly incidence); B) observed and predicted P. falciparum prevalence.
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the predicted prevalence, almost triplicating the maximum
and minimum prevalence in HTS and LTS, respectively
(Figure 3C and D). Furthermore, a reduction of the treat-
ment effectiveness from 0.98 (baseline value) to 0.80
would increase the incidence and prevalence by more than
100% and 150%, respectively.
Table S2 shows the predicted impact (after 1 and 5
years) on the P. falciparum incidence after the addition
of different FSAT interventions according to timing and
number of interventions. Conducting one FSAT interven-
tion with microscopy alone between July and September
during only one year would have a larger impact on the
P. falciparum incidence than conducting it during any
other month, with a reduction of about 20% and 15%,
respectively at 1- and 5 years post intervention.
However, the magnitude of this effect would be twice
as high if PCR is used instead of microscopy, reaching
reductions of more than 40% and 30% respectively at
1- and 5 years after intervention. Similarly, the impact
on P. falciparum prevalence was the highest when
FSAT was added in LTS (in August), instead of in HTS
(in February) during only one year (Figure 4A), with a
significant reduction in the maximum prevalence
reached during the next HTS (p < 0.05), i.e. from
12.3% (baseline prevalence) to 9.6% (using microscopy)
or to 6.0% (if PCR is used).
The strongest decrease in P. falciparum malaria inci-
dence for interventions implemented during only one
year was observed with three consecutive FSAT starting
at the beginning of LTS and separated by time intervals
of 7 to 60 days (Additional file 5: Table S2), resulting in
reductions of more than 40% and 30%, respectively after
1 and 5 years when using microscopy, and of more than
80% and 75%, respectively when using PCR. The impact
of the number of consecutive FSAT at the start of LTS
(one to three FSAT during only one year, separated by
intervals of 30 days) on the predicted P. falciparum
prevalence is shown in the Figure 4B. While three con-
secutive FSATs using PCR would have the largest effect
on the predicted prevalence, one FSAT alone using PCR
would result in a similar reduction compared to three
consecutive FSATs using microscopy. In all simulations
including PCR, annual P. falciparum incidence and
prevalence would return slowly to the initial levels after
10 years, if FSAT interventions are implemented only
during one year.
Figure 4C shows a progressive reduction of the predicted
prevalence with annually repeated FSAT interventions
Figure 3 Sensitivity analysis for the baseline model. Changes in: A) annual overall incidence (baseline model prediction: 152 infections); B) annual
asymptomatic incidence (baseline: 53 infections); C) maximum prevalence during the year (baseline: 12.3%); D) minimum prevalence during the
year (baseline: 3.5%). Results are expressed in percentage of change (%) in comparison with baseline model predictions.
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starting at the beginning of LTS every year. All repeated
interventions would reach the near-zero prevalence,
however the rate of decrease largely depends on the
number of monthly FSAT per year and the diagnosis
test used for malaria detection. Indeed, while three-
monthly FSATs using microscopy would require
approximately 10 years to reach the zero level preva-
lence; this could be reached with three monthly FSATs
using PCR for four consecutive years. However, a de-
crease in the fraction of symptomatic infections from
0.65 to 0.5, or a decrease in the treatment effectiveness
from 0.98 to 0.8, would substantially reduce the rate of
progression to the elimination levels with FSATs using
microscopy (Figure 5A), and consequently increase the
time required to reach the elimination levels to more
than 20 years. Furthermore, if a reduction of FSAT
coverage from 100% to 80% is added to those scenarios,
P. falciparum prevalence would start to increase again
despite of the FSAT interventions. Conversely, if annu-
ally repeated FSAT interventions are implemented using
PCR, the effects of similar changes (i.e. decrease in the
fraction of symptomatic infections, in the treatment effect-
iveness, or in the FSAT coverage) on the P. falciparum
prevalence would be smaller, hence delaying the time to
reach zero prevalence levels only by one or two years (6 or
7 years after onset of interventions) (Figure 5B).
Discussion
Using a relatively straightforward mathematical model,
our analysis showed that targeting the asymptomatic
parasite reservoir with FSAT interventions, in addition
to routine PCD, would significantly reduce P. falciparum
malaria in low transmission areas of the Peruvian
Amazon. The strongest reduction was observed if three
consecutive FSAT were implemented annually at the
beginning of low transmission season, and if malaria
diagnosis was done with a highly sensitive field PCR.
Modelling the effects of interventions that target the
asymptomatic malaria reservoir requires a good know-
ledge of the burden of asymptomatic infections and their
transmission dynamics. Cross-sectional surveys in the
Peruvian Amazon reported that more than two thirds of
malaria infections were asymptomatic [3,4]; however
these studies did not take into account the incubation
period for some of them, hence the potential develop-
ment of symptoms at a later stage [9]. Therefore data
from the cohort study conducting in peri-Iquitos
communities including weekly monitoring of symptoms
for one month of all infected individuals, enabled to
overcome the limitations of previous survey results. In-
deed, an important proportion of P. falciparum infec-
tions which were asymptomatic at the time of detection
(either by microscopy or by retrospective PCR) developed
malaria symptoms (reported and/or measured fever) after
one week of follow-up [4], resulting in only 35% of
asymptomatic infections among all confirmed cases in the
Ninarumi community in 2004. Another study conducted
in the Brazilian Amazon in 2004–2005 found similar re-
sults after combining PCD and ACD over a 14-month
period, i.e. a total of 326 malaria infections were identified
Figure 4 Model-predicted P. falciparum prevalence curves after the addition of different FSAT interventions to the baseline PCD. A) one FSAT at
beginning of LTS only in year 0 (Y0) and in HTS only in year 1 (Y1), using microscopy or PCR; B) one to three successive FSAT starting at
beginning of LTS only in Y0, with microscopy or PCR; C) one to three successive FSAT starting at beginning of LTS for consecutive ten years
(from Y0 to Y10), with microscopy or PCR.
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of which 96 (29.4%) were asymptomatic– a much lower
proportion than reported in any of the cross-sectional sur-
veys carried out during the same period [35].
The cohort study also allowed for an accurate
measurement of seasonal variations in the incidence of
symptomatic and asymptomatic P. falciparum infections
in the area, and these seasonal dynamics were well
reproduced by the baseline model. In addition, the
model predicted not only a 2–3 times higher prevalence
of infections during the peak of HTS than during the
LTS, but also temporal differences in the proportion of
asymptomatic infections, which accounted for about
60% of all prevalent infections during the peak of HTS
while they represented almost all infections in the
middle of LTS. Moreover, the proportion of prevalent
infections detectable by microscopy (“patent infections”)
varied also with season, i.e. from almost 50% (6.2% of a
total prevalence of 12.3%) in the HTS to 20% (0.7% of a
total prevalence of 3.4%) in the LTS. Those predictions
suggest that in areas of low and seasonal transmission
such as the Peruvian Amazon, non-detectable asymp-
tomatic P. falciparum infections are able to persist
during the LTS being potentially infectious to mosqui-
toes emerging after the start of the rains, as previously
described in other areas with markedly seasonal
transmission [36,37].
Since symptomatic P. falciparum infections are more
likely to be identified and treated during PCD, and the
duration of treated infections is considerably shorter
than untreated infections; it is anticipated that potential
changes in the fraction of symptomatic infections as
well as in the effectiveness of case management, may
significantly impact the malaria prevalence as shown
by the sensitivity analysis. Indeed, simulations showed
that a decrease in the fraction of symptomatic infec-
tions from 0.65 to 0.5 or a decrease in the treatment
effectiveness from 0.98 to 0.8 resulted in similar effects
as changes in entomological parameters (ratio female
mosquitoes to humans from 75 to 90, human feeding
rate by 20%) which are known as being important
determinants for the vectorial capacity and the malaria
transmission [38]. Asymptomatic infections are becoming
increasingly common at low transmission levels [3-12,21],
enlarging the human infectious reservoir which will enable
onward transmission. On the other hand, treatment
effectiveness can decrease due to the spread of drug-
resistant strains of P. falciparum parasites and the lack of
systems that assure the quality of both the antimalarial
drugs and the case management procedures (e.g. poor
prescribing practices by health workers, low patient adher-
ence rates to treatment regimens) [22,39].
In contrast to the current strategy of the National
Malaria Control Program consisting of adding FSAT
with microscopy to PCD during HTS in prioritized lo-
calities of the Peruvian Amazon [14], our simulations
showed that conducting a single FSAT at the beginning
of LTS would not only result in a greater reduction in
P. falciparum incidence and prevalence in the short
term, but also decrease the progression rates of these
indicators to the initial levels. Furthermore, the effect
of FSAT would be maximal if three successive FSAT at
time intervals of 7–60 days, would be implemented at
the start of the LTS. Kern et al. found a similar impact
on the P. falciparum transmission with a single FSAT
Figure 5 Long-term impact of changes in the fraction of symptomatic infections and the treatment effectiveness on the maximum predicted
P. falciparum prevalence after the onset of annual FSAT interventions (three successive FSAT at beginning of LTS): A) FSAT interventions using
microscopy for malaria screening; B) FSAT interventions using PCR for malaria screening.
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with microscopy during the dry season using a
seasonally-forced malaria model which incorporated
periodically mosquito birth rates through a sinusoidal
function and different levels of infectiousness for
gametocyte carriers; however, while in areas of simu-
lated low disease burden (entomological inoculation
rates (EIR) < 10 infective bites/person/year) such as
the Peruvian Amazon, the effect was sustained for over
three years after the intervention, in areas of high en-
demicity (EIR > 200) the incidence rates of infection
returned to their initial level in the subsequent year
[40]. Moreover, the study also indicated that three
FSAT scheduled at monthly intervals starting in the
dry season had the greatest positive impact on trans-
mission. Successive FSATs would not only allow for
identifying infected individuals who were in a latent
state at the time of the previous FSAT, but also would
increase the coverage of the intervention in real-life
situations by including individuals who were absent or
not eligible (illness, pregnancy) during the previous
FSAT. The relatively wide time interval (i.e. 7–60 days)
for a subsequent intervention suggested by our model
would facilitate the planning and logistics of mobile
teams in charge of FSAT in the targeted communities.
Beside timing and frequency of a given intervention, the
other important determinant of impact is the duration
(number of years) the intervention needs to be applied to
reach sustainable elimination levels. Our model suggested
that three successive FSAT with microscopy for ten con-
secutive years, would result in a sustained declining
P. falciparum prevalence and incidence and eventually
reach elimination levels. Long-term effects of FSAT has
been previously described by Griffin et al. using a
complex modelling approach (including immunity, super-
infections, and heterogeneity in transmission intensity) fed
with published transmission parameters and local epi-
demiological data of different endemic areas of Africa
[41]. The results showed that in low-to-moderate trans-
mission settings, 80% coverage of annual single round of
FSAT using rapid diagnostic tests (RDTs) over 15 years,
together with 80% coverage of insecticide treated nets
(ITNs), would reduce the absolute parasite prevalence by
5–12%. On the other hand, in high transmission areas, the
simulated impact of FSAT alone was marginal, the ultim-
ate outcomes strongly depending on the initial transmis-
sion level, the frequency and duration of the intervention
and the coverage of vector control (i.e. either ITN or in-
door residual spraying) [41].
As a consequence of increased use of molecular tests
for detecting submicroscopic malaria infections in both
low and high-malaria transmission settings, as well as of
recent studies reporting failures of FSAT to reduce
transmission when using microscopy or RDTs [42], it
has been suggested that PCR based strategies need to be
deployed if such interventions are to be successful [43,44].
Our model simulations assessed the impact of FSAT inter-
ventions using an assumed field PCR with high sensitivity,
under the assumption that any level of gametocyte density
was potentially infectious [45]. Repeated FSAT interven-
tions with PCR for several consecutive years would not
only have a stronger impact on P. falciparum malaria
transmission (halving time to reach elimination levels),
but would also enable to sustain the impact despite even-
tual reductions in the proportion of symptomatic infec-
tions, treatment effectiveness and/or coverage of FSAT.
Although these results support the importance of
detecting and treating sub-microscopic infections at point
of care for successful elimination strategies [22,46], imple-
menting FSAT using PCR as routine strategy in prioritized
localities of the Peruvian Amazon may not be feasible
since current PCR tests are resource-intensive, time-
consuming and expensive [47]. Recently, some studies
have shown high sensitivity of non-conventional molecu-
lar tests based on loop-mediated isothermal amplification
(LAMP) with no requirement for specialist staff and ex-
pensive equipment [48]; these molecular tests need to be
optimized quickly to be used in the field for species-
specific identification of Plasmodium parasites.
Like with other mathematical models for malaria trans-
mission, our predictions should be interpreted taking into
account the underlying assumptions. Some assumptions
were intended to simplify the complex malaria dynamics
(e.g. constant mosquito and human populations, no indi-
vidual differences in transmission parameters between
subjects), while others attempted to fill the knowledge gap
in the P. falciparum malaria transmission cycle (e.g. the
development of mature gametocytes in all infected indi-
viduals, potential for transmission of any infectious indi-
vidual independently of its gametocyte density in blood).
Further research is still needed to define to what extend
asymptomatic and submicroscopic malaria infections con-
tribute to the infectious reservoir [49]; this information
would considerably improve our model. In addition, after
the development of a more complex model for P. vivax
transmission using data of a recent cohort carried in the
Peruvian Amazon [12], it will help to further fine-tune the
model and define operational criteria for FSAT interven-
tions to maximize the impact of the intervention on both
species.
Conclusions
Our model suggested that FSAT combined to PCD en-
ables to reach elimination levels in an area of low trans-
mission of the Amazon Region, but the progression rates
to those levels vary substantially according to the oper-
ational criteria used for the intervention (i.e., timing, num-
ber, coverage, and duration of FSAT) and the sensitivity of
the diagnostic test used for malaria screening. Despite its
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limitations, the modelling approach can contribute to de-
sign new field studies in the Peruvian Amazon to assess
the effectiveness of FSAT and other strategies to further
decrease malaria transmission. Even before easy-to-use
molecular tests will be available at the point of care, as
well as reliable evidence of the effectiveness of FSAT, the
current strategy applied by the NMCP in Peru should be
revised in the light of our results in order to be more cost
effective. Programmatic FSAT interventions with micros-
copy (minimum of two successive FSAT) can be con-
ducted at the beginning of the LTS in areas with known
high risk of P. falciparum malaria transmission, trying to
reach the maximum population coverage (avoiding areas
with highly mobile populations). Alternatively to reach the
areas of mobile populations, resources could be invested to
implement a “smart surveillance system” based on reactive
case detection guided by information from the PCD.
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